Nevertheless, nivolumab 12 or atezolizumab 13 treatment led to a clinically relevant improvement of survival versus docetaxel in treated NSCLC patients, regardless of PD-L1 expression level. The gene discussed is CD274; the disease is non-small cell lung carcinoma.